Cipla Q3 results FY25 reported a 49% year-on-year increase in consolidated net profit to ₹1,571 crores. On the Cipla results date which was January 28, 2025, the Cipla share price opened at ₹1,395.05 and it closed with a jump at ₹1,420.60. So, let’s get into the details of Cipla Q3 results and segment revenues.
Cipla Q3 Results FY25: Key Highlights
- Cipla consolidated PAT rose to ₹1,571 in the Q3 of FY25, 49% higher than the ₹1,056 crores of Q3 FY24.
- Consolidated revenue was at ₹7,073, up 7% YoY according to the Cipla Q3 results of FY25.
- EBITDA rose by 16% YoY to ₹1,989 crores in Q3 of FY25 from ₹1,720 crores in the Q3 of FY24.
- The total debt was at ₹466 crores as on December 31, 2024, and it was 1.08% YoY higher than the ₹461 crores as on December 31, 2023.
- As on December 31, 2024, Cash & Cash Equivalents (CCE) was ₹9,413 crores, up 11.90% YoY from ₹8,412 crores as on December 31, 2023.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Particulars | Q3 FY25 | Q3 FY24 | Y-o-Y Change |
---|---|---|---|
Net Profit | 1,571 | 1,056 | 49% |
Revenue | 7,073 | 6,604 | 7% |
EBITDA | 1,989 | 1,720 | 16% |
*(in ₹ crores)
Cipla Q3 Results: Segment Revenue
- One India business revenue grew by 10% YoY led by the growth in branded prescription business, trade generics, and anchor brands.
- North America’s quarterly revenue of $226 million was led by a growth in differentiated assets and it helped in overcoming the Lanreotide supply shortfall.
- One Africa had a revenue growth of 10% YoY and the company’s prescription business was ranked first in the market as per the Cipla Q3 results press release.
Segment Revenue | Q3 FY25 | Q3 FY24 | Y-o-Y Change |
---|---|---|---|
India | 3,146 | 2,859 | 10% |
North America | 1,906 | 1,916 | -1% |
One Africa | 975 | 883 | 10% |
Emerging Markets and Europe | 824 | 678 | 22% |
API | 126 | 108 | 17% |
*(in ₹ crores)
Cipla Q3 Results: Management Commentary
Umang Vohra, MD and Global CEO of Cipla commented: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite of a supply challenge in the U.S.
We recorded a revenue growth of 8% over last year with a highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in Branded Prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track and Anchor brands of Consumer Health Business maintained leadership position.
With a positive traction in our differentiated assets, the US business posted a revenue of $ 226 Mn. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging Markets and Europe delivered a substantial revenue growth of 20% YoY on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.”
Highlighting the Cipla share price performance, it has generated a positive return of approximately 2% on Tuesday, January 28, 2025. Keep exploring stocks and open demat account with SMC Global Securities. Stay tuned for the upcoming Nifty 50 companies quarterly results.
References:
SMC Global Securities Research Team
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account